Floatz logo

Dasminapant

Advanced Solid Tumors or Hematologic Malignancies

Ascentage Pharma Group Inc.Small moleculePhase 1Dormant
C
38/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
23/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Advanced Solid Tumors or Hematologic Malignancies cohort.

Asset / SponsorPhaseRating
Apg-1387 For
Ascentage Pharma Group Inc.
Phase 1C

Same molecule, other indications

Dasminapant is also rated in:

Advanced Pancreatic CancerDormant
C
Indicative ·
38 / 100
View asset →
Advanced Solid TumorDormant
C
Indicative ·
33 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →